12:00 AM
Jul 05, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Taspoglutide: Additional Phase III data

Additional data from the double-blind, international Phase III T-emerge 1 trial in 373 treatment-naïve Type II diabetics showed that 10 and 20 mg subcutaneous weekly taspoglutide significantly reduced HbA1c by 1.01% and 1.18%, respectively, from baseline to week 24 vs. 0.09% for placebo (p<0.001 for both). Additionally, a greater proportion of patients receiving low- and high-dose taspoglutide achieved a reduction in HbA1c to <7% at week 24 vs. placebo (65% and 71%, respectively, vs. 20%).

High-dose taspoglutide also significantly reduced body weight from baseline to week...

Read the full 411 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >